Stock Screener App

Gratuito -

Installare

2.79

7.31% 0.19

after-market

Dopo l'orario di chiusura: 2.79

Atossa Therapeutics Inc (ATOS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie

Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma

ATOS: Multiple Catalysts Converge in 2H26 - Smartkarma

Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance

Atossa Therapeutics pursues ESR1 mutation research to tackle endocrine resistance in breast cancer - Traders Union

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Atossa Therapeutics shifts clinical focus to pre-surgical breast cancer patients - Traders Union

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Atossa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Weekly Recap: Q2 net loss, financing and (Z)-endoxifen Phase 2 progress - TradingView

Atossa Therapeutics reports Q2 2026 results, ad... - Pluang

Atossa Therapeutics Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView

Atossa Therapeutics investigates (Z)-endoxifen for McCune-Albright syndrome and endocrine disorders - Traders Union

Atossa Therapeutics (ATOS) Advances Clinical Pipeline Amid Valua - GuruFocus

Form 8K Atossa Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada

Atossa Therapeutics Q2 net loss widens on lower interest income - TradingView

Atossa Therapeutics reports Q2 2026 net loss $8.5M, cash $26.1M; advances (Z)-endoxifen programs - TradingView

ATOS: Q2 2026 net loss was $8.5M; (Z)-endoxifen programs advanced and $4.5M in new capital raised - TradingView

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire

ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary - TradingView

Atossa Therapeutics (NASDAQ: ATOS) posts $18.1M loss, flags going concern risk - Stock Titan

Atossa Genetics (ATOS) Earnings Date and Reports 2026 $ATOS - MarketBeat

Atossa Therapeutics strengthens pipeline with new data on Z-endoxifen breast cancer therapy - Traders Union

Calendrier des fractionnements d'actions pour: - Yahoo Finance France

CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView

Atossa Therapeutics advances rare disease pipeline with (Z)-endoxifen strategy - Traders Union

Atossa Therapeutics advances biomarker-driven Z-endoxifen treatment for breast cancer - Traders Union

Atossa Therapeutics (ATOS) Focuses on Execution Amid Challenging Valuation and Mixed Guru Interest - GuruFocus

Atossa study shows preclinical activity in breast cancer models By Investing.com - Investing.com South Africa

Atossa Therapeutics (ATOS) Unveils Promising Preclinical Breast Cancer Study Amidst Challenging Valuation - GuruFocus

Atossa study shows preclinical activity in breast cancer models - Investing.com

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - Morningstar

Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Atossa Therapeutics (ATOS) Gains 4.6%: Biotech Stock Tests Key ResistanceETF Flow - dars.gov.et

TradingKey - TradingKey

Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Amidst Pre-Revenue StageAnalyst Consensus Shift - dars.gov.et

Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

ATOS|Atossa Therapeutics Inc|Price:2.295|Chg%:-0.115 - TradingKey

ATOSSA THERAPEUTICS, INC. advances omics and organoid research in rare cancer field - Traders Union

Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxi - GuruFocus

Atossa Therapeutics (ATOS) Unveils Promising Data for (Z)-Endoxifen in Rare Disease Treatment - GuruFocus

Atossa Therapeutics highlights (Z)-endoxifen's dual action for rare McCune-Albright Syndrome treatment. - Pluang

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - PR Newswire

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The News-Press

Price to sales forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView

Enterprise value to revenue forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView

Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Atossa Therapeutics (ATOS) Edges Higher as Stock Hovers Near Key Resistance LevelRunaway Gap - dars.gov.et

Atossa Therapeutics sends Sandra S Hammer to AACR rare cancer event in Vancouver - Traders Union

ATOS Should I Buy - Intellectia AI

Price to cash flow ratio of Atossa Therapeutics, Inc. – DUS:YAG - TradingView

ATOS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Investor ReactionQuarterly Profit Report - dars.gov.et

ATOSSA THERAPEUTICS, INC. explores lessons from COVID-19 for future biosecurity strategies - Traders Union

Rodman & Renshaw Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $12 - Moomoo

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - AOL.com

ATOS Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus

Rodman & Renshaw initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com South Africa

Rodman & Renshaw initiates Atossa Genetics stock with buy rating - Investing.com

ATOSAtossa Therapeutics Inc Short Interest - Finviz

Nona Biosciences Partners with Atossa Therapeutics to Advance Next-Generation Antibody Therapies for Breast Cancer - BioPharma APAC

Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Nigeria

Atossa Therapeutics (ATOS) Surges 5.7% as Biotech Momentum BuildsUnusual Call Volume - dars.gov.et

MRNA

$64.46

1.80%

ROIV

$36.24

0.11%

RPRX

$59.45

1.45%

INSM

$128.32

3.70%

ALNY

$224.60

1.77%

ONC

$362.51

4.33%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters